Prinomastat
Title: Prinomastat
CAS Registry Number: 192329-42-3
CAS Name: (3S)-N-Hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide
Additional Names: 3(S)-N-hydroxy-4-((4-((pyrid-4-yl)oxy)benzenesulfonyl)-2,2-dimethyl)tetrahydro-2H-1,4-thiazine-3-carboxamide
Manufacturers' Codes: AG-3340
Molecular Formula: C18H21N3O5S2
Molecular Weight: 423.51
Percent Composition: C 51.05%, H 5.00%, N 9.92%, O 18.89%, S 15.14%
Literature References: Selective matrix metalloproteinase inhibitor with antiangiogenic activity. Prepn: S. E. Zook et al., WO 9720824; S. L. Bender, M. J. Melnick, US 5753653 (1997, 1998 both to Agouron). Pharmacokinetic and antitumor efficacy in rats: O. Santos et al., Clin. Exp. Metastasis 15, 499 (1997). Review of pharmacology: D. R. Shalinsky et al., Ann. N.Y. Acad. Sci. 878, 236-270 (1999); and clinical experiences: R. Scatena, Expert Opin. Invest. Drugs 9, 2159-2165 (2000).
Properties: White powder, mp 149.8°. Also reported as 184-186° with gas evolution. Water soluble.
Melting point: mp 149.8°
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic Adjunct; Antimetastatic Agent; Matrix Metalloproteinase Inhibitor.

Others monographs:
TetrafluoroethyleneBeryllium Potassium SulfateCalcium BromideTubercidin
p-Aminosalicylic Acid HydrazideAnhalamineChromic Fluoride3,4-Dinitrobenzoic Acid
FibrinIsoetharineTobacco Mosaic VirusRamatroban
AcequinocylThiamorpholineProcainamide HydrochlorideRostaporfin
©2016 DrugLead US FDA&EMEA